The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen (NCT01890486)
The Prospective Collection, Storage and Reporting of Data on Patients
🩺 Plain-English Summary (8th-Grade Level)
To provide the IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (1 items) and avoid the listed exclusions (1 items).
Location: Wake Forest Baptist Health — Winston-Salem, North Carolina
Age range: 18 Years to 120 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria: Participation in any other treatment research protocol
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Wake Forest Baptist Health — Winston-Salem, North Carolina
📞 Contact the Study Coordinator
Phone: (336) 716-2843
Email: dhurd@wakehealth.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Myelogenous Leukemia
- Allo HSCT Using RIC and PTCy for Hematological Diseases — Minneapolis, Minnesota
- Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia — Los Angeles, California
- ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis — Cleveland, Ohio
- Cord Blood Transplantation in Children and Young Adults With Blood Cancer — New York, New York
- ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies — Orange, California
Explore by condition: All Acute Myelogenous Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.